Erectile Dysfunction Market Report 2026

The erectile dysfunction market size has grown strongly in recent years. It will grow from $2.68 billion in 2025 to $2.92 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to aging male population, cardiovascular disease prevalence, pde5 inhibitor adoption, urology clinic expansion, lifestyle-related health issues.

The erectile dysfunction market size is expected to see strong growth in the next few years. It will grow to $4.06 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to telehealth growth, non-invasive therapy innovation, regenerative medicine research, stigma reduction awareness, personalized men’s health solutions. Major trends in the forecast period include rising use of oral drug therapies, growing adoption of non-invasive devices, expansion of telemedicine-based consultations, increased awareness of men’s health, emphasis on personalized treatment approaches.

The rising prevalence of lifestyle-related diseases is expected to drive the growth of the erectile dysfunction market. Lifestyle-related diseases are health conditions primarily caused by unhealthy habits, including poor diet, lack of physical activity, smoking, and excessive alcohol consumption. Factors such as sedentary lifestyles, poor nutrition, stress, and unhealthy habits like smoking and excessive drinking contribute to this increase. Erectile dysfunction (ED) often serves as an early indicator of lifestyle-related diseases, including cardiovascular conditions and diabetes, emphasizing the need for timely medical intervention and healthier lifestyle choices. For instance, in 2024, the World Obesity Federation, a UK-based non-profit organization, reported that by 2035, 79% of adults with overweight and obesity will reside in Low- and Middle-Income Countries (LMICs), and 88% of children with overweight and obesity will live in LMICs by the same year. Therefore, the rising prevalence of lifestyle-related diseases is expected to propel the growth of the erectile dysfunction market.

Major companies in the erectile dysfunction market are focusing on innovative products, such as over-the-counter (OTC) gels, to offer more accessible and convenient treatment options for individuals experiencing erectile dysfunction, thereby expanding market reach and addressing unmet patient needs. An OTC gel is a topical medication available without a prescription, applied directly to the skin to treat various conditions. For instance, in September 2024, Haleon plc, a UK-based consumer healthcare company, launched Eroxon, the first FDA-cleared over-the-counter gel for erectile dysfunction. This product provides a non-invasive, fast-acting solution for ED, enhancing accessibility and convenience for patients. Its topical application eliminates the need for oral medications, reducing the risk of systemic side effects.

In July 2023, Futura Medical plc, a UK-based provider of sexual health products including Eroxon® (MED3000), partnered with Haleon plc to commercialize Eroxon® in the United States. Under this collaboration, Haleon manages the product’s marketing, regulatory approvals, and commercial launch, while Futura provides technical support and ongoing product expertise. This partnership underscores the growing emphasis on bringing innovative erectile dysfunction therapies to new markets through strategic commercialization collaborations. Haleon plc is a UK-based consumer healthcare company.

Major companies operating in the erectile dysfunction market are Pfizer Inc., Bayer AG, Dong-A Socio Holdings Co. Ltd., Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Limited, Sandoz International GmbH, Sun Pharmaceutical Industries Limited, Coloplast Corporation, Dr. Reddy's Laboratories Limited, Cipla Limited, Ferring Pharmaceuticals A/S, Endo International plc, Zydus Lifesciences Limited, Lupin Limited, Hims & Hers Health Inc., Cadila Pharmaceuticals Limited, VIVUS Inc., Rigicon Inc., Petros Pharmaceuticals Inc., Futura Medical plc, Apricus Biosciences Inc., Initiator Pharma A/S.

North America was the largest region in the erectile dysfunction market in 2025. The regions covered in the erectile dysfunction market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the erectile dysfunction market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the erectile dysfunction market by increasing costs of imported pharmaceuticals, medical devices, and diagnostic equipment. Hospitals, clinics, and pharmacies in developed regions are most affected due to reliance on imported therapies. These tariffs raise treatment costs by increasing drug procurement expenses and device pricing for oral therapies, injectables, and implantable solutions, affecting patient affordability and access. However, they promote domestic manufacturing of ED drugs and devices, encouraging local production of generics, injectables, and mechanical aids to reduce long-term import dependence.

The erectile dysfunction market research report is one of a series of new reports that provides erectile dysfunction market statistics, including erectile dysfunction industry global market size, regional shares, competitors with a erectile dysfunction market share, detailed erectile dysfunction market segments, market trends and opportunities, and any further data you may need to thrive in the erectile dysfunction industry. This erectile dysfunction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Erectile dysfunction (ED) is the inability to achieve or maintain an erection adequate for satisfactory sexual performance. It is a common condition influenced by various physical, psychological, and lifestyle factors, impacting men’s overall well-being and quality of life.

The main product types for treating erectile dysfunction include drugs and devices. Drugs are chemical formulations designed to improve blood flow to the penis, helping men achieve and sustain an erection. These products are distributed through hospital pharmacies, retail pharmacies, and online channels, and are used by end users such as hospitals and clinics, ambulatory surgery centers, pharmacies, and others.

The erectile dysfunction market consists of sales of medications, devices, and therapies aimed at treating erectile dysfunction. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.